Journal Title：Lancet Respiratory Medicine

The Lancet Respiratory Medicine delivers comprehensive, clinically-focused coverage on all areas of respiratory medicine and critical care, including but not limited to: COPD, asthma, cystic fibrosis, IPF, pneumonia, influenza, tuberculosis, sarcoidosis, pulmonary hypertension, sleep medicine, respiratory infections, pulmonary vascular disease, lung cancer, tobacco control, thoracic and reconstructive surgery, mesothelioma, and palliative medicine. Continuing in The Lancet's tradition of publishing high-impact content that influences medical practice, each monthly issue of The Lancet Respiratory Medicine contains Original Research, Reviews, Personal Views, Comments, and News.

The Lancet Respiratory Medicine is stringently edited and peer-reviewed to ensure the scientific merit and clinical relevance of its diverse content. Original Research is fast-tracked to publication within 8 weeks of submission (on average) and published Online First on www.thelancet.com before appearing in print.

Now indexed in PubMed, Journal Citation Reports?, and Scopus, the journal accepts submissions of Original Research, Reviews, Personal Views, and Comments. Visit http://ees.elsevier.com/thelancetrm to learn more about our editorial scope and aims and to submit your manuscript.

Gold or Green Open Access is available for research supported by selected funding agencies with whom Elsevier has an agreement. The journal is also freely available to readers in low-to-middle-income countries via the HINARI programme or via IP access at www.thelancet.com.

To find out more about The Lancet Respiratory Medicine, visit www.thelancet.com/respiratory.

《柳葉刀呼吸醫(yī)學(xué)》全面、以臨床為重點，涵蓋呼吸醫(yī)學(xué)和重癥監(jiān)護的所有領(lǐng)域，包括但不限于：慢性阻塞性肺病、哮喘、囊性纖維化、特發(fā)性肺纖維化、肺炎、流感、結(jié)核病、結(jié)節(jié)病、肺動脈高壓、睡眠醫(yī)學(xué)、呼吸道感染、肺血管疾病、肺癌、煙草控制、胸外科和重建外科、間皮瘤和姑息醫(yī)學(xué)。《柳葉刀呼吸醫(yī)學(xué)》延續(xù)了《柳葉刀》發(fā)表影響醫(yī)學(xué)實踐的高影響力內(nèi)容的傳統(tǒng)，每月一期，都包含原創(chuàng)研究、評論、個人觀點、評論和新聞。

《柳葉刀呼吸醫(yī)學(xué)》經(jīng)過嚴(yán)格編輯和同行評審，以確保其多樣化內(nèi)容的科學(xué)價值和臨床相關(guān)性。原創(chuàng)研究在提交后 8 周內(nèi)（平均）即可快速發(fā)表，并在 www.thelancet.com 上在線發(fā)表，然后才印刷出來。

該期刊現(xiàn)已被 PubMed、Journal Citation Reports? 和 Scopus 收錄，接受原創(chuàng)研究、評論、個人觀點和意見的投稿。請訪問 http://ees.elsevier.com/thelancetrm 詳細了解我們的編輯范圍和目標(biāo)，并提交您的稿件。

黃金或綠色開放獲取適用于 Elsevier 與之有協(xié)議的選定資助機構(gòu)資助的研究。該期刊還可通過 HINARI 計劃或通過 www.thelancet.com 上的 IP 訪問免費提供給中低收入國家的讀者。

要了解有關(guān)《柳葉刀呼吸醫(yī)學(xué)》的更多信息，請訪問 www.thelancet.com/respiratory。

Lancet Respiratory Medicine創(chuàng)刊于2013年，由Elsevier Ltd出版商出版，收稿方向涵蓋RESPIRATORY SYSTEM - RESPIRATORY SYSTEM全領(lǐng)域，在行業(yè)領(lǐng)域中學(xué)術(shù)影響力很大，屬于TOP期刊，國際一流期刊，關(guān)注度和專業(yè)度非常高，所以對原創(chuàng)文章要求創(chuàng)新性很高，過審難度很高，如果您有志于TOP期刊，建議關(guān)注此刊。平均審稿速度 ，影響因子指數(shù)38.7，該期刊近期沒有被列入國際期刊預(yù)警名單，廣大學(xué)者值得一試。